Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
about
Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and managementCharacterization of schizophrenia adverse drug interactions through a network approach and drug classificationAtypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Timing and frequency of physostigmine redosing for antimuscarinic toxicity.Sertindole: efficacy and safety in schizophrenia.Metabolic drug interactions with newer antipsychotics: a comparative review.Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.A review of the safety and tolerability of aripiprazole.Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.Atypical antipsychotics: trends in analysis and sample preparation of various biological samples.A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review.Clinically significant drug interactions with atypical antipsychotics.Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia.Neuroprotective effects of quetiapine on neuronal apoptosis following experimental transient focal cerebral ischemia in rats.Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients
P2860
Q28268128-617D9FE2-C730-4940-905F-81CD05080429Q28679280-371E4112-3B22-4B26-911D-B925C3BA0C6FQ30486391-CBCEEEF9-8C71-4FEF-A935-9D2DB75E799EQ33223628-CDDFBEBD-47E1-4E0D-8B0B-A5610D64986BQ33799660-74807E56-52E2-43D3-ABE8-6BEA53731A66Q34554423-D8638217-9989-4D06-AA48-0E987B3C7998Q36549565-8B525BD8-7BCE-4CC6-B991-A64A7E9681D9Q36573915-40039CCE-AAEB-4345-A884-A946E81653B4Q36703845-330746A2-B096-4020-994C-FEBA9CFB4BF1Q37038991-BC9F14B6-CEDC-4716-954C-C8852735AFA3Q37175786-34DEE621-8F62-4530-9EC6-85985A99E452Q37510958-AD254E17-FEF0-412E-8CC4-9918A6245F22Q37709400-2898762A-5D82-4CDB-9B11-C01EEE36B330Q38005440-BD03EF83-062F-4582-988F-E50181BC64A6Q38132166-78E99A22-07D8-4903-9422-B92C125AE87CQ38156416-EDCB1746-B150-41A7-92CA-B1CF1BBDA16AQ38284625-7E7D6340-C09E-428A-9657-8D7299D9B656Q38734067-0E9BC196-364B-46D6-B8A1-815BA7DB164EQ39959170-0188621C-933D-447A-B90B-3DAE90B5B080Q41118477-3EAD5974-F13F-45A4-9CC9-F82F398E972CQ41998343-C5974093-ED94-4C68-A33E-0855A63F4C97Q46727005-DB5F05BA-8D20-4C4C-A57F-3ADCE622F643Q56974058-0605EFD8-746B-4F21-AD5A-EE57F5505928
P2860
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Atypical antipsychotics: pharm ...... pharmacological interactions.
@ast
Atypical antipsychotics: pharm ...... pharmacological interactions.
@en
type
label
Atypical antipsychotics: pharm ...... pharmacological interactions.
@ast
Atypical antipsychotics: pharm ...... pharmacological interactions.
@en
prefLabel
Atypical antipsychotics: pharm ...... pharmacological interactions.
@ast
Atypical antipsychotics: pharm ...... pharmacological interactions.
@en
P2093
P356
P1476
Atypical antipsychotics: pharm ...... pharmacological interactions.
@en
P2093
Cesare Sabbioni
Maria Augusta Raggi
Vincenzo Pucci
P304
P356
10.2174/0929867043456089
P577
2004-02-01T00:00:00Z